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Dear Editor, 
 
Cell attachment or adhesion, either to another cell or a matrix, is a critical feature of many 
cell types. For example, immune cells attach to endothelial cells that make up the blood ves-
sels before they enter inflamed tissue. Attachment to the endothelium by circulating tumor 
cells is also a critical step in metastasis. Therefore, it is of high interest to identify key factors 
that modify a cell’s ability to attach.  
In a recent issue of Cell Adhesion and Migration, Lesjak and colleagues demonstrated that 
choline metabolism strongly influences adhesion of breast and ovarian cancer cells to a fi-
bronectin matrix (Lesjak et al., 2014). In this study, the authors focused on EDI3 (synonym: 
GDE5 or GPCD1) a key enzyme in choline metabolism that was recently shown to cleave 
glycerophosphocholine (GPC) in tumor cells (Stewart et al., 2012). One of the cleavage prod-
ucts is choline, the substrate of choline kinase (Marchan et al., 2012). Currently, many studies 
focus on choline kinase as a potential target for cancer therapy; indeed, expression of this en-
zyme has been shown to be increased in many carcinomas (Iorio et al., 2005, 2010; Gallego-
Ortega et al., 2011; Ramírez de Molina et al., 2002a, b). The second cleavage product of EDI3 
is glycerol-3-phosphate, which can further be metabolized to lysophosphatidic acid, phospha-
tidic acid and diacylglycerol (Stewart et al., 2012). 
A key experiment in the present study of Lesjak et al. (2014) was that silencing EDI3 in 
breast and ovarian cancer cell lines reduced expression of integrin beta 1. This key integrin 
receptor can bind to any one of a number of integrin alpha receptors, thus influencing binding 
to different extracellular matrices, such as fibronectin, laminin and collagen. The binding or 
heterodimerization of alpha-beta integrins also regulates integrin-mediated signaling, which 
controls processes such as migration, proliferation, differentiation, attachment and even death 
(Spangenberg et al., 2006).  In addition to reduced integrin beta 1 expression, silencing of 
EDI3 in these two cancer cell lines resulted in decreased attachment and spreading on a fi-
bronectin matrix. Conversely, overexpressing EDI3 led to enhanced integrin beta 1 expres-
sion, increased attachment and spreading. However, a question that still remains open is the 
mechanism by which EDI3 influences integrin expression. 
There is currently a great deal of research focused on understanding which mechanisms 
influence tumor metastasis and prognosis of carcinomas (Schmidt et al., 2008; Cadenas, 2012; 
Lesjak et al., 2014; Thanopoulou and Judson, 2012; Mamas et al., 2011; Hammad, 2013). 
Typical factors of influence include adhesion molecules (Micke et al., 2014; Schmidt et al., 
2008; 2011; Botling et al., 2013), components of the immune system (Schmidt et al., 2012; 
Godoy et al., 2014), and redox factors (Cadenas et al., 2010). Although much effort is invest-
ed towards elucidating the influence of tumor metabolism on cancer development, the present 
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study of Lesjak et al. (2014) is the first to link choline metabolism to tumor cell attachment. 
These initial observations set the stage for future studies which will focus on whether choline 
metabolism can be pharmaceutically modified to reduce the capacity of tumor cells to attach 
and form metastasis. 
 
 
REFERENCES 
Botling J, Edlund K, Lohr M, Hellwig B, Holmberg 
L, Lambe M et al. Biomarker discovery in non-small 
cell lung cancer: integrating gene expression profil-
ing, meta-analysis, and tissue microarray validation. 
Clin Cancer Res 2013;19:194-204.  
Cadenas C. Prognostic signatures of breast cancer: 
Perou's molecular subtypes and Schmidt's metagenes. 
EXCLI J 2012;11:204-7. 
Cadenas C, Franckenstein D, Schmidt M, Gehrmann 
M, Hermes M, Geppert B et al. Role of thioredoxin 
reductase 1 and thioredoxin interacting protein in 
prognosis of breast cancer. Breast Cancer Res 
2010;12(3):R44. 
Gallego-Ortega D, Gómez del Pulgar T, Valdés-Mora 
F, Cebrián A, Lacal JC. Involvement of human cho-
line kinase alpha and beta n carcinogenesis: a differ-
ent role in lipid metabolism and biological functions. 
Adv Enzyme Regul 2011;51:183-94. 
Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart 
J, Reif R et al. Interferon-inducible guanylate binding 
protein (GBP2) is associated with better prognosis in 
breast cancer and indicates an efficient T cell re-
sponse. Breast Cancer 2014;21:491-9. 
Hammad S. Interaction of genetic variants towards 
increased cancer risk. EXCLI J 2013;12:625-7. 
Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ra-
moni C, D’Ascenzo S et al. Alterations of choline 
phospholipid metabolism in ovarian tumor progres-
sion. Cancer Res 2005;65:9369-76. 
Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano 
G, Di Vito M et al. Activation of phosphatidylcholine 
cycle enzymes in human epithelial ovarian cancer 
cells. Cancer Res 2010;70:2126-35. 
Lesjak MS, Marchan R, Stewart JD, Rempel E, Rah-
nenführer J, Hengstler JG. EDI3 links choline me-
tabolism to integrin expression, cell adhesion and 
spreading. Cell Adh Migr 2014;8(4) (pp 1-10). 
Mamas M, Dunn WB, Neyses L, Goodacre R. The 
role of metabolites and metabolomics in clinically 
applicable biomarkers of disease. Arch Toxicol 2011; 
85:5-17.  
Marchan R. Lung and breast cancer research: immu-
noglobulin Kappa C hits the headlines. EXCLI J 
2012;11:237-9. 
Marchan R, Lesjak MS, Stewart JD, Winter R, Seeli-
ger J, Hengstler JG. Choline-releasing glycerophos-
phodiesterase EDI3 links the tumor metabolome to 
signaling network activities. Cell Cycle 2012;11: 
4499-506. 
Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, 
Berglund A et al. Aberrantly activated claudin 6 and 
18.2 as potential therapy targets in non-small-cell 
lung cancer. Int J Cancer 2014;135:2206-14. 
Ramírez de Molina A, Gutiérrez R, Ramos MA, Silva 
JM, Silva J, Bonilla F et al. Increased choline kinase 
activity in human breast carcinomas: clinical evidence 
for a potential novel antitumor strategy. Oncogene 
2002a;21:4317-22. 
Ramírez de Molina A, Rodríguez-González A, 
Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F 
et al. Overexpression of choline kinase is a frequent 
feature in human tumor-derived cell lines and in lung, 
prostate, and colorectal human cancers. Biochem Bio-
phys Res Commun 2002b;296:580-3. 
Schmidt M, Hasenclever D, Schaeffer M, Boehm D, 
Cotarelo C, Steiner E et al. Prognostic effect of epi-
thelial cell adhesion molecule overexpression in un-
treated node-negative breast cancer. Clin Cancer Res 
2008;14:5849-55. 
Schmidt M, Petry IB, Böhm D, Lebrecht A, von Tör-
ne C, Gebhard S et al. Ep-CAM RNA expression pre-
dicts metastasis-free survival in three cohorts of un-
treated node-negative breast cancer. Breast Cancer 
Res Treat 2011;125:637-46. 
Schmidt M, Hellwig B, Hammad S, Othman A, Lohr 
M, Chen Z et al. A comprehensive analysis of human 
gene expression profiles identifies stromal immuno-
globulin κ C as a compatible prognostic marker in 
human solid tumors. Clin Cancer Res 2012;18:2695-
703.  
Spangenberg C, Lausch EU, Trost TM, Prawitt D, 
May A, Keppler R et al. ERBB2-mediated transcrip-
tional up-regulation of the alpha5beta1 integrin fi-
bronectin receptor promotes tumor cell survival under 
adverse conditions. Cancer Res 2006;66:3715-25. 
EXCLI Journal 2014;13:856-858 – ISSN 1611-2156 
Received: August 12, 2014, accepted: August 19, 2014, published: August 19, 2014 
 
 
858 
Stewart JD, Marchan R, Lesjak MS, Lambert J, Her-
genroeder R, Ellis JK et al. Choline-releasing glycer-
ophosphodiesterase EDI3 drives tumor cell migration 
and metastasis. PNAS 2012;109:8155–60. 
Thanopoulou E, Judson I. The safety profile of 
imatinib in CML and GIST: long-term considerations. 
Arch Toxicol 2012;86:1-12. 
